24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825
Fax: (361)578-5500

Child & Adolescent Development: Overview
Resources
Basic InformationMore InformationLatest News
Most U.S. Parents Say Vaccination Should Be Requirement for School: PollIf a Child's Schoolwork Slips, Don't Rule Out Hearing LossNurturing Childhood Boosts Odds of a Happy Adult Life: StudyKids in Poor Neighborhoods Face Higher Odds for Obesity as AdultsA Prescription for Medicating Your Child SafelyIs a Charter School the Right Choice for Your Child?Health Tip: Mental Illness Warning SignsAn Easy Recipe for Healthier Back-to-School LunchesAHA News: Understanding Connection Between Poverty, Childhood Trauma and Heart DiseaseHealth Tip: Staying Well During the School YearBackpacks Shouldn't Be a Back-to-School Burden on HealthA Kid-Friendly Emergency Room Saves LivesMany Parents Would Switch Doctors Over Vaccination Policy, Poll FindsAs School Starts, Pack That Lunch With Nutritional Goodies5 Health Tips to Promote Back-to-School SuccessPot Poisonings Among Kids, Teens Double After Medical Marijuana Law PassedFor Kids Born With HIV, Taking Needed Meds Gets Harder With Age: StudyBuilding a Better BackpackKids Getting Too Many Opioids After TonsillectomyExplaining, Easing the Horror of Mass Shootings for Your KidsFor Kids With Asthma, Allergies, New School Year Can Bring Flare-UpsAnother Video Game Risk to Watch Out ForOlder Parents May Have Better Behaved KidsAre Too Many Kids Prescribed Antihistamines?Childhood Cancer Steals Over 11 Million Years of Healthy Life: StudyFamily Home, Football Field Most Dangerous Spots for Kids' Head InjuriesMost Airplanes Not Equipped With First Aid for KidsPlastics Chemicals Meant to Replace BPA May Not Be Any Safer for KidsWhat Happens to the Children When Parents Fight?Health Tip: Giving Medicine Safely to ChildrenHow to Make Your Child's Hospital Stay Safer, Less StressfulObesity May Boost Odds for MS in KidsHealth Tip: Diarrhea in KidsOpioid Epidemic Doubled Number of U.S. Kids Sent to Foster CareSwimming Lessons a Must for EveryoneHow to Help When Your Child Weighs Too MuchHave Kids, Buy More Produce?Zika's Damage Continues in Children Infected Before BirthCDC Warns of Start to 'Season' for Mysterious Paralyzing Illness in KidsParent Who Listens Can Help Kids Thrive Despite TraumaHealth Tip: Ear Piercing For KidsReacting Against a 'Too Clean' World, Some Parents Go Too Far the Other WaySurvey Urges Grandparents to Lock Down Their Meds When Kids VisitCalifornia Took on Anti-Vaxxers, and WonHow Does Sunshine During Pregnancy Affect Learning?Surgery Helps Babies Missing a Heart Chamber Survive, But Problems LingerAbuse, Injury More Likely When Child is With Male Caregiver: StudyHow to Foster Your Child's ImaginationLow Vitamin D at Birth Linked to Kids' High Blood Pressure RiskHow Do Kids Learn To Turn Off Troublesome Tics?
Questions and AnswersLinks
Related Topics

ADHD: Attention Deficit Hyperactivity Disorder
Childhood Mental Disorders and Illnesses
Child Development & Parenting: Infants (0-2)
Child Development & Parenting: Early (3-7)

FDA Expands Cystic Fibrosis Treatment Approval to Children Ages 6 to 12


HealthDay News
Updated: Jun 24th 2019

new article illustration

MONDAY, June 24, 2019 (HealthDay News) -- The indication for a cystic fibrosis treatment, Symdeko (tezacaftor/ivacaftor) tablets, has been expanded to treat children ages 6 years and older with cystic fibrosis and certain genetic mutations, the U.S. Food and Drug Administration announced today.

Symdeko is approved to treat patients with two copies of the F508del mutation, the most common type of mutation, and patients who have at least one of the mutations in the CFTR gene that is responsive to the active ingredients in Symdeko. The FDA approved Symdeko last year for treatment in children ages 12 years and older with the same genetic mutations. Dosage in children ages 6 to 12 years weighing less than 30 kg is one tablet of 50 mg tezacaftor and 75 mg ivacaftor in the morning and one tablet of 75 mg ivacaftor approximately 12 hours later. In patients aged 12 years and older or who weigh 30 kg or more, dosage is one tablet containing 100 mg tezacaftor and 150 mg ivacaftor and a tablet containing 150 mg ivacaftor 12 hours later.

Symdeko's approval was based on three phase 3, double-blind, placebo-controlled trials that showed improvements in lung function and a reduction in exacerbations. The expanded indication approval to children ages 6 to 12 years was based on data from patients aged 12 years and older and additional support from data on patients aged 6 to 12 years. Symdeko's safety in children ages 6 to 12 years was demonstrated in a 24-week, open-label study of 70 cystic fibrosis patients aged 6 to 12 years.

Symdeko's labeling indicates that it should always be taken with food containing fat and should never be combined with certain antibiotics, seizure medications, St. John's wort, or food containing grapefruit or Seville oranges. The prescribing information includes warnings of elevated transaminases and the risk for cataracts in children taking Symdeko and warns against taking Symdeko simultaneously with CYP3A inducers. The most commonly reported side effects were headache, nausea, sinus congestion, and dizziness.

Approval was granted to Vertex Pharmaceuticals.

More Information